JP2001519815A - アレルゲン誘発性障害の治療におけるラクトフェリンの使用 - Google Patents

アレルゲン誘発性障害の治療におけるラクトフェリンの使用

Info

Publication number
JP2001519815A
JP2001519815A JP54315498A JP54315498A JP2001519815A JP 2001519815 A JP2001519815 A JP 2001519815A JP 54315498 A JP54315498 A JP 54315498A JP 54315498 A JP54315498 A JP 54315498A JP 2001519815 A JP2001519815 A JP 2001519815A
Authority
JP
Japan
Prior art keywords
lactoferrin
inflammatory
tnf
induced
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP54315498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001519815A5 (https=
Inventor
キンバー，イアン
カンバーバッチ，マリー
ディアマン，レベッカ・ジェイ
コネリー，オーラ・エム
ウォード，ポーリーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of JP2001519815A publication Critical patent/JP2001519815A/ja
Publication of JP2001519815A5 publication Critical patent/JP2001519815A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP54315498A 1997-04-10 1998-04-10 アレルゲン誘発性障害の治療におけるラクトフェリンの使用 Ceased JP2001519815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4189097P 1997-04-10 1997-04-10
US60/041,890 1997-04-10
PCT/US1998/007234 WO1998044940A1 (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Publications (2)

Publication Number Publication Date
JP2001519815A true JP2001519815A (ja) 2001-10-23
JP2001519815A5 JP2001519815A5 (https=) 2005-11-24

Family

ID=21918897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54315498A Ceased JP2001519815A (ja) 1997-04-10 1998-04-10 アレルゲン誘発性障害の治療におけるラクトフェリンの使用

Country Status (12)

Country Link
US (1) US20030190303A1 (https=)
EP (1) EP0979099B1 (https=)
JP (1) JP2001519815A (https=)
CN (1) CN1262625A (https=)
AT (1) ATE297755T1 (https=)
AU (1) AU747385C (https=)
CA (1) CA2285960A1 (https=)
DE (1) DE69830582T2 (https=)
ES (1) ES2245028T3 (https=)
IL (1) IL132293A0 (https=)
NZ (1) NZ500712A (https=)
WO (1) WO1998044940A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501772A (ja) * 2004-06-11 2008-01-24 シンジェンタ リミテッド 炎症性皮膚状態を寛解するための方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL336626A1 (en) * 1997-05-03 2000-07-03 Regents Board Of Methods of preventing and treating traumatic loss of metabolic equlibrium among human beings and animals
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU782539B2 (en) * 2000-01-14 2005-08-04 Meiji Dairies Corporation Antigen-specific IgE antibody production inhibitors
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
CA2471766C (en) * 2001-12-28 2011-01-11 Nrl Pharma, Inc. Compositions for improving lipid metabolism
EP2543385A1 (en) 2002-01-21 2013-01-09 NRL Pharma, Inc. Novel analgesics
CN100467059C (zh) 2002-05-10 2009-03-11 阿根尼克斯有限公司 乳铁蛋白在治疗恶性肿瘤疾病中的用途
US7238661B2 (en) * 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
DE60335997D1 (de) * 2002-09-16 2011-03-24 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
CA2508912A1 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
CN101166535A (zh) * 2005-03-15 2008-04-23 坎皮纳荷兰控股有限责任公司 乳蛋白的皮肤病学应用
US8178486B2 (en) * 2005-07-21 2012-05-15 Animal Technology Institute Taiwan Method for promoting hair growth
EP1937298A4 (en) * 2005-10-14 2009-11-11 Auckland Uniservices Ltd USE OF LACTOFERRIN FRAGMENTS AND HYDROLYSATES
JPWO2007049757A1 (ja) * 2005-10-27 2009-04-30 サンスター株式会社 ラクトフェリンを含んだリポソームを含有する破骨細胞増加抑制剤、経口組成物及び骨疾患の予防又は治療剤
EP3210618A1 (en) * 2010-04-23 2017-08-30 Probiotec Limited Composition comprising lactoferrin and immunoglobulin for the treatment of eczema
CN102370964B (zh) * 2010-08-16 2015-12-09 李兴德 白细胞介素受体拮抗蛋白在制备皮肤外用制剂中的应用
IT201800002457A1 (it) * 2018-02-07 2019-08-07 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
PL4072322T3 (pl) * 2019-12-11 2025-05-19 N.V. Nutricia Kompozycja do żywienia do poprawy sprawności układu odpornościowego
EP4526469A1 (en) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596986B1 (fr) * 1986-04-11 1988-09-23 Sederma Sa Utilisation de la lactoferrine dans des preparations cosmetiques, antiradicaux libres
FR2641696B2 (fr) * 1986-04-11 1991-03-08 Sederma Sa Utilisation d'un melange renfermant de la lactoferrine dans des preparations cosmetiques anti-radicaux libres
FR2685202B1 (fr) * 1991-12-24 1995-03-24 Sederma Sa Nouvelle methode de traitement pharmaceutique et cosmetique pour la regulation de la seborrhee, de l'acne et de la flore cutanee.
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
JPH05279266A (ja) * 1992-04-02 1993-10-26 Imuno Japan:Kk 歯周病の治療・予防用医薬組成物
JP3163171B2 (ja) * 1992-07-15 2001-05-08 森永乳業株式会社 ＩｇＡ産生促進剤
JP3746081B2 (ja) * 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
JPH0859450A (ja) * 1994-08-18 1996-03-05 Kose Corp 皮膚外用剤
JP2832517B2 (ja) * 1994-12-09 1998-12-09 雪印乳業株式会社 大腸菌付着阻止剤
JP3911642B2 (ja) * 1995-06-06 2007-05-09 株式会社加美乃素本舗 皮膚外用剤
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501772A (ja) * 2004-06-11 2008-01-24 シンジェンタ リミテッド 炎症性皮膚状態を寛解するための方法

Also Published As

Publication number Publication date
CN1262625A (zh) 2000-08-09
NZ500712A (en) 2002-10-25
DE69830582T2 (de) 2006-05-04
AU6964798A (en) 1998-10-30
EP0979099B1 (en) 2005-06-15
AU747385B2 (en) 2002-05-16
WO1998044940A1 (en) 1998-10-15
ATE297755T1 (de) 2005-07-15
CA2285960A1 (en) 1998-10-15
IL132293A0 (en) 2001-03-19
ES2245028T3 (es) 2005-12-16
US20030190303A1 (en) 2003-10-09
EP0979099A1 (en) 2000-02-16
AU747385C (en) 2003-01-30
DE69830582D1 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
JP2001519815A (ja) アレルゲン誘発性障害の治療におけるラクトフェリンの使用
DE68905438T2 (de) Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose.
CA2907574C (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells
JP7511296B2 (ja) ペプチド並びにそれを含む化粧料組成物及び薬学組成物
JP2003526622A (ja) 老化防御効果を示すテトラペプチド、これを基にした薬理学的物質、及びその利用法
JP2001519786A (ja) 創傷治癒用医薬の製造のためのオキシトシン活性を有する物質の使用
JP2003518066A (ja) オリゴ糖を含む組成物、特に化粧品用または皮膚科用組成物、その調製方法、および化粧品処置方法
AU2001275018B2 (en) Composition and method for enhancing elasticity of tissue
DE69031563T2 (de) Behandlung der autoimmunen uveoretinitis in menschen
US20050054578A1 (en) Elastin peptide analogs and uses thereof
JP4689039B2 (ja) ファゴサイトーシスおよびｉｃａｍ−１発現を調節するための組成物および方法
US7666842B2 (en) Elastin peptide analogs and uses thereof
AU2001275018A1 (en) Composition and method for enhancing elasticity of tissue
JP2014177464A (ja) Ｍｎｔｆペプチドの美容および皮膚科用製剤
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
Dati et al. Beneficial effects of rh-CLU on disease severity in different animal models of peripheral neuropathies
US6809075B1 (en) Elastin peptide analogs and uses of same incombination with skin enhancing agents
JP6934051B2 (ja) 皮膚炎症抑制用ペプチドおよびそれを含む皮膚炎症の予防または治療用組成物
KR100756974B1 (ko) 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
JP2003509466A (ja) コルチコトロピン放出ホルモンアナログを使用する異常な細胞増殖の阻害
MXPA99009240A (en) Use of lactoferin in the treatment of allergen induced disorders
RU2586286C2 (ru) Применение для лечения и профилактики атеросклероза белково-пептидного комплекса (далее-бпк), полученного из эмбриональной нервной ткани или из быстрозамороженного эмбрионального мозга сельскохозяйственных копытных животных, влияющего на обратный транспорт холестерина из сосудистой стенки и профиль активации моноцитов у пациентов с выраженным атеросклерозом магистральных сосудов или с предрасположенностью к сердечно-сосудистым заболеваниям и способ профилактики и лечения пациентов с атеросклерозом артериальных сосудов и с заболеваниями, вызванными атеросклерозом магистральных и периферических сосудов головного мозга, сердца, сосудов нижних конечностей и аорты (два варианта)
KR20220164450A (ko) Agkistrodon piscivorus piscivorus 또는 Naja melanoleuca로부터 유래된 신규한 펩타이드, 및 이를 포함하는 베체트병 또는 류마티스 관절염의 치료용 조성물
US7605132B2 (en) Protective factors against inflammation, burns and noxious stimuli
KR20170050540A (ko) 메트포민을 유효성분으로 포함하는 피부질환 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080930

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090512